July 2026 – Clinical Trial Results

Dr. Tyler De Jong and Dr. C. Michael Gibson discuss DrKumo, a digital health platform that applies artificial intelligence to remote patient monitoring, with the aim of integrating real time patient data into clinical workflows, reducing administrative burden, and supporting timely, efficient, and individualized patient management.

July 28, 2026

Disclosures: TBD

New insights into the heart-kidney connection in ATTR-CM. Dr. Jeffrey Testani and Dr. C. Michael Gibson discuss new analyses showing that acoramidis was associated with early and sustained kidney-protective effects in patients with ATTR-CM—findings that may help explain the therapy’s early cardiovascular benefits and offer new perspectives on cardiorenal health.

July 24, 2026

Supported by an independent educational grant from BridgeBio Inc.

Aortic dissection is a life-threatening emergency where every minute matters. In this interview, Dr. Firas Mussa and Dr. C. Michael Gibson discuss the key signs and symptoms clinicians should recognize, why early diagnosis is so critical, and how the IMPROVE-AD trial aims to advance the care of patients with acute aortic dissection.

July 20, 2026

Disclosures: TBD

From humble beginnings to leading one of the nation’s premier cardiovascular programs, Dr. Samin Sharma and Dr. C. Michael Gibson talk about the journey that shaped his career and what lies ahead in his new role as Chief of Cardiology at Mount Sinai.

July 6, 2026

Disclosures: TBD

Atrial fibrillation affects up to 70% of patients with ATTR-CM—but how does it impact treatment outcomes?

July 1, 2026

Dr. Brett Sperry and Dr. C. Michael Gibson discuss new findings showing that acoramidis delivered consistent clinical benefits regardless of […]